Table 1:

Ongoing or recently completed randomized trials in neuroendocrine tumors

Sponsor (NCT Trial No.)	Experimental Arm	Control Arm	Tumor Type
SWOG (NCT00569127)	Bevacizumab + octreotide LAR	IFN-α-2b + octreotide LAR	Carcinoid
Novartis (NCT 00412061)	Everolimus+ octreotide LAR	Octreotide LAR	Carcinoid
Novartis (NCT 00690430)	Pasireotide	High-dose octreotide	Refractory carcinoid syndrome
Ipsen (NCT 00353496)	Lanreotide autogel	Placebo	Carcinoid or pancreatic NET
Pfizer (NCT 00428597)	Sunitinib	Placebo	Pancreatic NET*
Novartis (NCT 00510068)	Everolimus	Placebo	Pancreatic NET

^*Accrual stopped early for efficacy

Abbreviations: NET = neuroendocrine tumor; SWOG = Southwest Oncology Group